Therefore, thanks to this study, it can be stated that myeloid cell-specific A20-/- mice can be used as a pre-clinical models for the validation of therapies for RA that have the aim of modifying inflammasome or IL-1 signaling [150]. This evidence concerns the gene IL1A and rheumatoid arthritis.